Brokerages Set Aclaris Therapeutics Inc (ACRS) Target Price at $41.25
Shares of Aclaris Therapeutics Inc (NASDAQ:ACRS) have received an average rating of “Hold” from the seven research firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $41.25.
A number of equities analysts have issued reports on ACRS shares. Cantor Fitzgerald reiterated a “buy” rating and set a $50.00 price target on shares of Aclaris Therapeutics in a research note on Tuesday, November 7th. Zacks Investment Research upgraded Aclaris Therapeutics from a “hold” rating to a “buy” rating and set a $31.00 price target for the company in a research note on Tuesday, October 10th. JMP Securities reiterated an “outperform” rating and set a $39.00 price target on shares of Aclaris Therapeutics in a research note on Friday, September 8th. BidaskClub upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, August 16th. Finally, ValuEngine downgraded Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, September 12th.
Hedge funds have recently added to or reduced their stakes in the business. Citigroup Inc. boosted its stake in Aclaris Therapeutics by 171.8% during the 2nd quarter. Citigroup Inc. now owns 4,313 shares of the biotechnology company’s stock valued at $117,000 after purchasing an additional 2,726 shares during the last quarter. UBS Group AG lifted its position in shares of Aclaris Therapeutics by 60.4% during the 1st quarter. UBS Group AG now owns 4,462 shares of the biotechnology company’s stock worth $133,000 after buying an additional 1,681 shares in the last quarter. Legal & General Group Plc lifted its position in shares of Aclaris Therapeutics by 98.3% during the 2nd quarter. Legal & General Group Plc now owns 5,254 shares of the biotechnology company’s stock worth $142,000 after buying an additional 2,605 shares in the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of Aclaris Therapeutics during the 3rd quarter worth approximately $142,000. Finally, Bank of Montreal Can lifted its position in shares of Aclaris Therapeutics by 1,793.1% during the 2nd quarter. Bank of Montreal Can now owns 7,137 shares of the biotechnology company’s stock worth $194,000 after buying an additional 6,760 shares in the last quarter. Institutional investors and hedge funds own 92.10% of the company’s stock.
Shares of Aclaris Therapeutics (NASDAQ:ACRS) traded down $1.44 on Thursday, hitting $22.27. The stock had a trading volume of 631,400 shares, compared to its average volume of 316,145. Aclaris Therapeutics has a 12 month low of $21.47 and a 12 month high of $33.25.
Aclaris Therapeutics (NASDAQ:ACRS) last issued its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.63) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.86) by $0.23. The firm had revenue of $0.68 million during the quarter, compared to analyst estimates of $2.00 million. analysts anticipate that Aclaris Therapeutics will post -2.59 earnings per share for the current year.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.
Receive News & Ratings for Aclaris Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.